<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04603027</url>
  </required_header>
  <id_info>
    <org_study_id>EDP1815-201</org_study_id>
    <nct_id>NCT04603027</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Cohort, Dose-Ranging Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evelo Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Evelo Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2 study has been designed to investigate the clinical safety and efficacy of&#xD;
      EDP1815 and to identify an optimal dose in subjects with mild to moderate psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel-cohort,&#xD;
      dose-ranging study of participants with mild to moderate plaque psoriasis. This Phase 2 study&#xD;
      has been designed to investigate the clinical safety and efficacy of EDP1815 and to identify&#xD;
      an optimal dose in subjects with mild to moderate psoriasis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 21, 2020</start_date>
  <completion_date type="Anticipated">December 6, 2021</completion_date>
  <primary_completion_date type="Actual">July 2, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a multicenter, randomized, double-blind, placebo-controlled, parallel-cohort, dose-ranging study of participants with mild to moderate plaque psoriasis</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percentage change in PASI</measure>
    <time_frame>16 weeks</time_frame>
    <description>The efficacy of EDP1815 will be measured using the mean percentage change in Psoriasis Area and Severity Index Score (PASI) from baseline to week 16</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean percentage change in PASI</measure>
    <time_frame>12 weeks</time_frame>
    <description>The efficacy of EDP1815 will be measured using the mean percentage change from baseline in Psoriasis Area and Severity Index Score (PASI) from baseline at weeks 4, 8, and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean absolute change in PASI</measure>
    <time_frame>16 weeks</time_frame>
    <description>The efficacy of EDP1815 will be measured using the mean absolute change from baseline in Psoriasis Area and Severity Index Score (PASI) from baseline at weeks 4, 8, 12, and 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of PASI-50</measure>
    <time_frame>16 weeks</time_frame>
    <description>The efficacy of EDP1815 will be measured using the achievement of PASI-50 at weeks 4, 8, 12, and 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first achievement of PASI-50</measure>
    <time_frame>16 weeks</time_frame>
    <description>The efficacy of EDP1815 will be measured using the time to first achievement of PASI-50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of PASI-75</measure>
    <time_frame>16 weeks</time_frame>
    <description>The efficacy of EDP1815 will be measured using the achievement of PASI-75 at week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of PASI-90</measure>
    <time_frame>16 weeks</time_frame>
    <description>The efficacy of EDP1815 will be measured using the achievement of PASI-90 at week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of PASI-100</measure>
    <time_frame>16 weeks</time_frame>
    <description>The efficacy of EDP1815 will be measured using the achievement of PASI-100 at week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of PGA of 0 or 1 with a ≥2-point improvement from baseline</measure>
    <time_frame>16 weeks</time_frame>
    <description>The efficacy of EDP1815 will be measured using the achievement of PGA of 0 or 1 with a ≥2-point improvement from baseline at Week 16 [PGA = Physician's Global Assessment]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of PGA of 0</measure>
    <time_frame>16 weeks</time_frame>
    <description>The efficacy of EDP1815 will be measured using the achievement of PGA of 0 at Week 16 [PGA = Physician's Global Assessment]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percentage change in PGAxBSA</measure>
    <time_frame>16 weeks</time_frame>
    <description>The efficacy of EDP1815 will be measured using the mean percentage change from baseline in PGA x BSA at Weeks 4, 8, 12, and 16. [PGA = Physician's Global Assessment, BSA = Body Surface Area]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean absolute change in PGAxBSA</measure>
    <time_frame>16 weeks</time_frame>
    <description>The efficacy of EDP1815 will be measured using the mean absolute change from baseline in PGA x BSA at Weeks 4, 8, 12, and 16. [PGA = Physician's Global Assessment, BSA = Body Surface Area]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percentage change in LSS</measure>
    <time_frame>16 weeks</time_frame>
    <description>The efficacy of EDP1815 will be measured using the mean percentage change from baseline in LSS (Lesion Severity Score) at Weeks 4, 8, 12, and 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean absolute change in LSS</measure>
    <time_frame>16 weeks</time_frame>
    <description>The efficacy of EDP1815 will be measured using the mean absolute change from baseline in LSS (Lesion Severity Score) at Weeks 4, 8, 12, and 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percentage change in DLQI</measure>
    <time_frame>16 weeks</time_frame>
    <description>The efficacy of EDP1815 will be measured using mean percentage change from baseline in Dermatology Life Quality Index (DLQI) at Weeks 4, 8, 12, and 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean absolute change in DLQI</measure>
    <time_frame>16 weeks</time_frame>
    <description>The efficacy of EDP1815 will be measured using the mean absolute change from baseline in Dermatology Life Quality Index (DLQI) at Weeks 4, 8, 12, and 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percentage change in mNAPSI</measure>
    <time_frame>16 weeks</time_frame>
    <description>The efficacy of EDP1815 will be measured using the mean percentage change in mNAPSI total score (modified Nail Psoriasis Severity Index) from baseline at Weeks 4, 8, 12, and 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean absolute change in mNAPSI</measure>
    <time_frame>16 weeks</time_frame>
    <description>The efficacy of EDP1815 will be measured using the mean absolute change in mNAPSI total score (modified Nail Psoriasis Severity Index) from baseline at Weeks 4, 8, 12, and 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of partial relapse</measure>
    <time_frame>40 weeks</time_frame>
    <description>The efficacy of EDP1815 will be measured by calculating the cumulative incidence of partial relapse at Weeks 20, 24, 28, and 40</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of complete relapse</measure>
    <time_frame>40 weeks</time_frame>
    <description>The efficacy of EDP1815 will be measured by calculating the cumulative incidence of complete relapse at Weeks 20, 24, 28, and 40</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of rebound</measure>
    <time_frame>40 weeks</time_frame>
    <description>The efficacy of EDP1815 will be measured by calculating the cumulative incidence of rebound at Weeks 20, 24, 28, and 40</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Psoriasis</condition>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 subjects with mild to moderate psoriasis; 50 on EDP1815, 25 on placebo. Dose = 0.8 x 10^11 cells, capsule, once daily, 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 subjects with mild to moderate psoriasis; 50 on EDP1815, 25 on placebo. Dose = 3.2 x 10^11 cells, capsule, once daily, 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 subjects with mild to moderate psoriasis; 50 on EDP1815, 25 on placebo. Dose = 8.0 x 10^11 cells, capsule, once daily, 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP1815</intervention_name>
    <description>EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo oral capsule</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Males or females ≥18 and ≤70 years old at the time of informed consent.&#xD;
&#xD;
          2. A documented diagnosis of plaque psoriasis for ≥6 months.&#xD;
&#xD;
          3. Have mild to moderate plaque psoriasis with plaque covering body surface area (BSA) of&#xD;
             ≥3% and ≤10% and meet both of the following additional criteria:&#xD;
&#xD;
               1. PASI score of ≥6 and ≤15, and&#xD;
&#xD;
               2. PGA score of 2 or 3.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Have a diagnosis of non-plaque psoriasis.&#xD;
&#xD;
          2. Plaque psoriasis restricted to scalp, palms, and soles only.&#xD;
&#xD;
          3. Have received systemic immunosuppressive therapy (MTX, apremilast, azathioprine,&#xD;
             cyclosporine, 6-thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, and&#xD;
             tacrolimus) within 4 weeks of first administration of study drug.&#xD;
&#xD;
          4. Unresponsive to prior use of biologics (including, but not limited to, TNFα&#xD;
             inhibitors, natalizumab, efalizumab, anakinra or agents that modulate B cells or T&#xD;
             cells).&#xD;
&#xD;
          5. If prior biologic therapy and responsive, participants must have been off therapy for&#xD;
             at least 12 months prior to first administration of study drug.&#xD;
&#xD;
          6. Have received phototherapy or any systemic medications/treatments that could affect&#xD;
             psoriasis or PGA evaluation (including, but not limited to oral or injectable&#xD;
             corticosteroids, retinoids, psoralens, sulfasalazine, hydroxyurea, or fumaric acid&#xD;
             derivatives) within 4 weeks of first administration of study drug. This includes&#xD;
             therapeutic doses of non-steroidal anti-inflammatory drugs such as ibuprofen, although&#xD;
             intermittent as required use as an analgesic is permitted when required. Chronic use&#xD;
             of low dose aspirin for cardiovascular protection is permitted.&#xD;
&#xD;
          7. Currently receiving lithium, antimalarials, leflunomide, or IM gold, or have received&#xD;
             lithium, antimalarials, IM gold, or leflunomide within 4 weeks of first administration&#xD;
             of study drug.&#xD;
&#xD;
          8. Have used topical medications/treatments that could affect psoriasis or PGA evaluation&#xD;
             (including [but not limited to] high- and mid-potency corticosteroids, anthralin,&#xD;
             calcipotriene, topical vitamin D derivatives, retinoids, tazarotene, methoxsalen,&#xD;
             trimethylpsoralens, picrolimus, and tacrolimus) within 2 weeks of the first&#xD;
             administration of study drug. Topical unmedicated emollients and low-potency topical&#xD;
             corticosteroids are not excluded.&#xD;
&#xD;
          9. Gastrointestinal tract disease (eg, short-bowel syndrome, diarrhea-predominant&#xD;
             irritable bowel syndrome) that could interfere with GI delivery and transit time.&#xD;
&#xD;
         10. Active inflammatory bowel disease.&#xD;
&#xD;
         11. Active infection requiring systemic antiviral or antimicrobial therapy that will not&#xD;
             be completed prior to Day 1 (Visit 2).&#xD;
&#xD;
         12. Have received live or live attenuated replicating vaccine within 6 weeks prior to&#xD;
             screening or intend to have such a vaccination during the study.&#xD;
&#xD;
         13. Clinically significant abnormalities in screening laboratory values that would render&#xD;
             a participant unsuitable for inclusion (per investigator judgment).&#xD;
&#xD;
         14. Known history of or positive test for HIV, or active infection with hepatitis C or&#xD;
             chronic hepatitis B.&#xD;
&#xD;
         15. History of clinically significant acute cardiac or cerebrovascular event within 6&#xD;
             months before screening (includes stroke, transient ischemic attack, and coronary&#xD;
             heart disease [angina pectoris, myocardial infarction, heart failure,&#xD;
             revascularization procedures]).&#xD;
&#xD;
         16. Current acute or chronic inflammatory disease other than psoriasis or psoriatic&#xD;
             arthritis (eg, inflammatory bowel disease, rheumatoid arthritis, systemic lupus&#xD;
             erythematosus). If a subject is off all treatment and is disease and has been symptom&#xD;
             free for greater than 12 months, then the inflammatory disease is considered to be in&#xD;
             remission and they may be enrolled.&#xD;
&#xD;
         17. Hypersensitivity to P histicola or to any of the excipients.&#xD;
&#xD;
         18. Active untreated mental or psychiatric disorder. Participants who are on stable dosing&#xD;
             of medication for a mental or psychiatric disorder for at least 6 months before&#xD;
             screening and whose treating physicians consider them to be mentally stable may be&#xD;
             enrolled.&#xD;
&#xD;
         19. Any major or minor GI surgery within 6 months of screening.&#xD;
&#xD;
         20. Any major surgery within 6 months of screening.&#xD;
&#xD;
         21. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or&#xD;
             carcinoma in situ of the cervix that has been successfully treated.&#xD;
&#xD;
         22. Treatment with another investigational drug, biological agent, or device within 1&#xD;
             month of screening, or 5 half-lives of investigational agent, whichever is longer.&#xD;
&#xD;
         23. Initiating any OTC or prescription medication including vitamins, herbal supplements&#xD;
             and nutraceuticals (eg, supplements including high doses of probiotics and prebiotics&#xD;
             as usually found in capsules/tablets/powders), except acetaminophen/paracetamol and&#xD;
             anti-histamines, within 14 days prior to baseline or anticipates change in dosage for&#xD;
             the duration of the study period. Note that probiotic and prebiotic foods that contain&#xD;
             low doses are allowed (eg, yoghurt, kefir, kombucha, however, supplements containing&#xD;
             high doses of probiotics and prebiotics are not allowed at any point during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Ehst, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Medical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Douglas Maslin, MPhil MBBS</last_name>
    <role>Study Director</role>
    <affiliation>Evelo Biosciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Santa Rosa</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - St. Petersburg</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - The Villages</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <zip>32162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Research Center PC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Anderson</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Budapest - Magyarország Egészségügyi Szolgáltató Kft</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Zalaegerszeg Magyarország Egészségügyi Kft</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - Wroclaw</name>
      <address>
        <city>Wrocław</city>
        <state>Dolnoslaskie</state>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - Gdansk</name>
      <address>
        <city>Gdańsk</city>
        <state>Pomorskie</state>
        <zip>80-382</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - Gdynia</name>
      <address>
        <city>Gdynia</city>
        <state>Pomorskie</state>
        <zip>81-537</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - Poznan</name>
      <address>
        <city>Poznań</city>
        <state>Wielkopolskie</state>
        <zip>60-702</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - Czestochowa</name>
      <address>
        <city>Czestochowa</city>
        <zip>42-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - Katowice</name>
      <address>
        <city>Katowice</city>
        <zip>40-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - Warszawa</name>
      <address>
        <city>Warszawa</city>
        <zip>01-192</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - Lodz</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - Thames Valley Clinical Research Centre</name>
      <address>
        <city>Reading</city>
        <state>Berkshire</state>
        <zip>RG2 0TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Blackpool</city>
        <state>Lancashire</state>
        <zip>FY2 0JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - Lancashire Clinical Research Centre</name>
      <address>
        <city>Chorley</city>
        <state>Lancashire</state>
        <zip>PR7 7NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - Merseyside Clinical Research Centre</name>
      <address>
        <city>Waterloo</city>
        <state>Liverpool</state>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicine Evaluation Unit</name>
      <address>
        <city>Wythenshawe</city>
        <state>Manchester</state>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Stockton-on-Tees</city>
        <state>North Yorkshire</state>
        <zip>TS17 6EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Cannock</city>
        <state>Staffordshire</state>
        <zip>WS11 0BN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - Wales Clinical Research Centre</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF15 9SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS10 1DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - Scotland Clinical Research Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G20 0SP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - Manchester Clinical Research Centre</name>
      <address>
        <city>Manchester</city>
        <zip>M15 6SE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PSO</keyword>
  <keyword>mild psoriasis</keyword>
  <keyword>moderate psoriasis</keyword>
  <keyword>plaque psoriasis</keyword>
  <keyword>psoriasis</keyword>
  <keyword>EDP1815</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

